What is the recommended initial management of acute kidney injury?

Initial Management of Acute Kidney Injury

Immediately discontinue all nephrotoxic medications—including NSAIDs, ACE inhibitors, ARBs, and diuretics—the moment AKI is recognized, as this single intervention prevents further renal injury and is the cornerstone of initial management. 1, 2

Diagnostic Confirmation and Staging

• Confirm AKI using KDIGO criteria: serum creatinine rise ≥0.3 mg/dL within 48 hours, OR ≥1.5× baseline within 7 days, OR urine output <0.5 mL/kg/h for ≥6 hours. 3, 2
• Stage the severity immediately: Stage 1 (1.5–1.9× baseline or ≥0.3 mg/dL rise), Stage 2 (2.0–2.9× baseline), Stage 3 (≥3.0× baseline, creatinine ≥4.0 mg/dL, or need for dialysis). 2
• Retrieve all prior creatinine values from the past 3–12 months to establish a true baseline and differentiate acute from chronic kidney disease; without this, you cannot accurately stage AKI. 2

Immediate Medication Actions

• Stop nephrotoxic drugs immediately: NSAIDs, ACE inhibitors, ARBs, diuretics, aminoglycosides, vancomycin, and any contrast agents. 1, 2, 4
• Avoid the "triple whammy" combination (NSAID + diuretic + ACE-I/ARB), which more than doubles AKI risk. 1
• Adjust all remaining medication dosages based on current estimated GFR and reassess daily as renal function changes. 1, 2

Determine the Underlying Cause

Classify AKI into prerenal, intrinsic renal, or postrenal categories to guide targeted therapy:

Prerenal (Volume Depletion or Hypoperfusion)

• Look for: recent vomiting, diarrhea, poor oral intake, diuretic overuse, hypotension, sepsis, heart failure, or cirrhosis. 2, 5
• Urinalysis clues: urine sodium <20 mEq/L or fractional excretion of sodium <1% suggests prerenal azotemia. 3, 6

Intrinsic Renal (Parenchymal Injury)

• Look for: recent nephrotoxin exposure, prolonged hypotension (acute tubular necrosis), new rash or fever (interstitial nephritis), hematuria with red-cell casts (glomerulonephritis). 2, 5
• Urinalysis clues: muddy-brown casts indicate ATN; red-cell casts suggest glomerulonephritis; white-cell casts point to interstitial nephritis or pyelonephritis. 3, 2

Postrenal (Obstruction)

• Look for: older male with prostatic hypertrophy, pelvic malignancy, bilateral kidney stones, or single functioning kidney with unilateral obstruction. 4, 6
• Obtain renal ultrasound immediately to rule out hydronephrosis or obstruction. 1, 2, 6

Volume Status Assessment and Fluid Management

• Assess volume status clinically: check jugular venous pressure, peripheral edema, daily weights, lung auscultation, and orthostatic vital signs. 1, 7
• For hypovolemic (prerenal) AKI: administer isotonic crystalloids (normal saline or lactated Ringer's) for volume expansion; avoid colloids and never use hydroxyethyl starch, which worsens kidney injury. 2, 4
• For euvolemic or hypervolemic patients: restrict fluids and avoid aggressive resuscitation, which worsens outcomes and can precipitate pulmonary edema. 1, 2
• In cirrhotic patients with AKI and creatinine doubling: give intravenous albumin 1 g/kg/day (maximum 100 g) for two consecutive days to expand intravascular volume. 1, 2

Laboratory Monitoring

• Measure serum electrolytes (Na⁺, K⁺, Ca²⁺, Mg²⁺, PO₄³⁻), BUN, and creatinine every 4–6 hours initially in Stage 2–3 AKI to detect life-threatening hyperkalemia, acidosis, or uremia. 1, 2, 7
• Perform urinalysis with microscopy to identify casts and guide etiologic diagnosis. 2, 6
• Track strict input-output measurements to quantify fluid balance and guide replacement therapy. 1, 7

Hemodynamic Support

• Use norepinephrine as the first-line vasopressor if hypotension persists after adequate fluid resuscitation; dopamine does not prevent or treat AKI and should not be used. 2
• Target mean arterial pressure >65 mmHg to ensure adequate renal perfusion. 2

Indications for Urgent Renal Replacement Therapy

Initiate dialysis immediately when any of the following are present:

• Severe oliguria (<0.3 mL/kg/h for ≥24 hours) unresponsive to fluid resuscitation. 1, 2
• Refractory hyperkalemia despite medical management. 2, 6
• Severe metabolic acidosis unresponsive to intravenous sodium bicarbonate. 2, 6
• Volume overload causing pulmonary edema refractory to diuretics. 2, 6
• Uremic complications (encephalopathy, pericarditis, or pleuritis). 2, 6

Nephrology Consultation

Obtain nephrology consultation in the following scenarios:

• Stage 3 AKI or any patient requiring dialysis. 2, 4
• AKI persisting >48 hours despite appropriate initial management. 2, 4
• Pre-existing chronic kidney disease Stage 4 or higher (eGFR <30 mL/min/1.73 m²). 2, 4
• Suspected glomerulonephritis, vasculitis, or rapidly progressive AKI. 2
• Underlying cause cannot be identified after initial evaluation. 2, 4

Special Considerations for Cirrhotic Patients

• Hold diuretics and β-blockers immediately when AKI develops in cirrhosis to prevent further renal hypoperfusion. 2
• Perform diagnostic paracentesis to rule out spontaneous bacterial peritonitis, as infection is a common AKI trigger in cirrhosis. 2
• Start broad-spectrum antibiotics empirically if infection is strongly suspected, without waiting for culture results. 2
• For hepatorenal syndrome: add vasoactive therapy (terlipressin preferred; or norepinephrine; or octreotide plus midodrine) in addition to albumin. 2

Common Pitfalls to Avoid

• Do not delay dialysis when clear indications exist; delaying RRT in Stage 3 AKI increases mortality. 1, 2
• Do not use loop diuretics to prevent or treat AKI; they provide no benefit and may cause harm. 2
• Do not apply eGFR equations (MDRD or CKD-EPI) during acute changes; they require steady-state creatinine and are validated only for stable CKD. 2
• Do not dismiss a modest absolute creatinine rise (≥0.3 mg/dL) as insignificant; even Stage 1 AKI is associated with a four-fold increase in hospital mortality. 2
• Do not correct severe hyponatremia too rapidly; this can cause osmotic demyelination syndrome. 1

Follow-Up After AKI

• Reassess kidney function at 3 months after the AKI episode to determine progression to chronic kidney disease. 2
• Schedule earlier follow-up (within 1–2 weeks) for Stage 3 AKI due to higher risk of CKD progression. 2
• Document the AKI episode clearly in the medical record and educate patients to avoid NSAIDs and seek prompt care for intercurrent illnesses. 2